Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCTI.L Regulatory News (CTI)

  • There is currently no data for CTI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update

25 Jul 2019 11:34

RNS Number : 7376G
Cathay International Holdings Ld
25 July 2019
 

 25 July 2019

Dissemination of a Regulatory Announcement that contains inside information according to REGULATION (EU) No 596/2014 (MAR).

Cathay International Holdings Limited

("Cathay", the "Company" or the "Group")

Trading update

Hong Kong, 25 July 2019 - Cathay International Holdings Limited (LSE: CTI.L), an operator and investor in the growing healthcare sector in the People's Republic of China (the "PRC"), provides a trading update for the six months ended 30 June 2019.

The Company expects a lower Group sales and profits in the first half 2019 than the same period last year.

As Lansen announced today in Hong Kong, Lansen expects to have noticeable decrease in its net profits for H1 2019 as compared with the net profit for H1 2018 due to the following reasons:

1. As stated in our 2018 annual report, Lansen has implemented a number of new strategic initiatives in its pharmaceutical business, in response to the challenging regulatory environment in China, by developing its own products such as Pafulin, Sicorten Plus, and certain featured pharmaceuticals; and reducing reliance on agency products. As a result, in the first half of the current financial year, Lansen's sales are below the same period last year.

2. A number of provisions and write-offs have been made against old and slow moving inventory.

3. As at 21 June 2019, Lansen decided not to exercise the put option (the "Put Option") to require Natural Dailyhealth to buy back its holding of 30% equity interest in Natural Dailyhealth. As a result, it has written off the related put option value.

Despite the short term impact on Lansen's results from the new strategic initiatives, Lansen sees improvement in its pharmaceutical segment and expects this segment's profit to be higher than that in same period last year, and looks forward to continuing improvement in the second half.

At Haizi, trading has been adversely impacted by a decrease in the market price for inositol and its results are expected to be below 2018.

Natural Dailyhealth and Botai are both trading broadly in line with expectations.

Our hotel remains profitable, although occupancy and average room rates are below last year and profits will be lower for the first half.

 

The Company's results for six months ended 30 June 2019 will be released in late August.

 

 

For further enquiries, please contact:

 

Cathay International Holdings Limited

Eric Siu (Finance Director)

Patrick Sung (Director and Controller)

 

 

Tel: +852 2828 9289

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal / Lindsey Neville

 

 

Tel: +44 (0) 203 709 5702

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTCKPDNKBKDDOB
Date   Source Headline
2nd Apr 20157:00 amRNSGrant of Share Options
30th Mar 20157:35 amRNSRepeat of Annual Results Announcement RNS 7096I
27th Mar 201512:14 pmRNSAnnual Results for the Year Ended 31 December 2014
25th Mar 20157:00 amRNSHolding(s) in Company
12th Mar 20157:00 amRNSNotice of Annual Results 2014
5th Jan 20159:16 amRNSLansen's New Distribution Agreement
18th Dec 20148:36 amRNSLansen and Haotian Renew Supply Agreement
29th Aug 20149:26 amRNSInterim results for six months ended 30 June 2014
19th Aug 20147:00 amRNSNotice of Interim Results 2014
23rd May 201410:38 amRNSResult of AGM
19th May 20147:00 amRNSInterim Management Statement
7th Apr 20148:58 amRNSGrant of Share Options
31st Mar 20147:00 amRNSAcquisition of Sicorten Plus in the PRC
28th Mar 20148:47 amRNSAnnual Results for the Year Ended 31 December 2013
14th Mar 20147:00 amRNSNotice of Annual Results
19th Nov 20137:00 amRNSInterim Management Statement
15th Oct 201310:24 amRNSTransfer of Misoprostol Development Project
3rd Sep 20131:31 pmRNSLansen and Haotian Sign Supply Agreement
30th Aug 20139:42 amRNSInterim Results for the six months ended June 2013
19th Aug 20139:24 amRNSNotice of Interim Results
21st May 20137:00 amRNSResults of Annual General Meeting
16th May 20137:00 amRNSInterim Management Statement
11th Apr 20137:00 amRNSAnnual Report and Accounts
4th Apr 20139:03 amRNSGrant of Share Options
27th Mar 20138:30 amRNSAnnual Results for the Year Ended 31 December 2012
14th Mar 20139:33 amRNSNotice of Annual Results 2012
6th Mar 20138:30 amRNSCathay's subsidiary Lansen board change
26th Feb 201310:37 amRNSTR-1: Notification of Major Interest in Shares
23rd Nov 20128:55 amRNS1.5% holding in Zhejiang Starry Pharmaceutical Co.
19th Nov 20127:00 amRNSInterim Management Statement
29th Aug 201212:15 pmRNSTotal Voting Rights and Share Capital
29th Aug 20129:23 amRNSInterim results
15th Aug 20127:00 amRNSNotice of Interim Results
25th May 201211:26 amRNSResult of AGM
21st May 20127:00 amRNSAnnual Information Update
17th May 20127:00 amRNSInterim Management Statement
10th May 20127:00 amRNSLicense for collagen injectable filler
20th Apr 20129:15 amRNSAnnual Report and Accounts
3rd Apr 201210:50 amRNSGrant of Share Options
29th Mar 20129:32 amRNSAnnual Results for the Year Ended 31 December 2011
19th Mar 201210:00 amRNSNotification of Annual Results
27th Feb 20129:43 amRNSLansen Received Technology Endorsement
9th Jan 20129:00 amRNSLansen signs exclusive agreement
18th Nov 20117:00 amRNSInterim Management Statement
26th Oct 20119:47 amRNSLansen signs exclusive agreement with Ethypharm
25th Aug 20115:00 pmRNSInterim Results
15th Aug 201111:12 amRNSNotice of Interim Results
20th May 20117:00 amRNSAnnual Information Update
19th May 20117:00 amRNSInterim Management Statement
6th Apr 20117:00 amRNSTotal Voting Rights and Share Capital

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.